Australia markets closed

KORU Medical Systems, Inc. (KRMD)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2500+0.0800 (+3.69%)
At close: 04:00PM EDT
2.2600 +0.01 (+0.44%)
After hours: 06:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1700
Open2.2100
Bid2.2100 x 500
Ask2.2700 x 200
Day's range2.1100 - 2.2500
52-week range1.9780 - 4.2950
Volume315,604
Avg. volume102,291
Market cap104.789M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

    MAHWAH, N.J., May 01, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024.

  • Business Wire

    KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

    MAHWAH, N.J., April 17, 2024--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financ

  • Business Wire

    KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

    MAHWAH, N.J., April 11, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI).